Purchase this article with an account.
Nohoon Kwak, Naoyuki Okamoto, Jeanette M. Wood, Peter A. Campochiaro; VEGF Is Major Stimulator in Model of Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2000;41(10):3158-3164.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. Vascular endothelial growth factor (VEGF) is upregulated by
hypoxia and is a major stimulatory factor for retinal
neovascularization in ischemic retinopathies such as diabetic
retinopathy. This study sought to determine if VEGF is a stimulatory
factor in a murine model of choroidal neovascularization (CNV).
methods. Mice with laser-induced ruptures in Bruch’s membrane were treated with
vehicle alone; a drug that inhibits both VEGF and platelet-derived
growth factor (PDGF) receptor kinases; a drug that inhibits PDGF, but
not VEGF receptor kinase; or genistein, a nonspecific kinase inhibitor.
After two weeks, CNV was quantified and compared. results. Blockade of phosphorylation by VEGF and PDGF receptors caused dramatic,
almost complete inhibition of CNV. Genistein also had an inhibitory
effect, but less so than the VEGF/PDGF receptor blocker. Blockade of
phosphorylation by PDGF receptors, but not VEGF receptors, had no
significant effect on cnv. conclusions. These data and our previous study, which demonstrated that a kinase
inhibitor that blocks VEGF and PDGF receptors and several isoforms of
protein kinase C causing dramatic inhibition of CNV, suggest that VEGF
signaling plays a critical role in the development of CNV in this
model. If safety is established, the effect of inhibiting VEGF receptor
kinase activity should be investigated in patients with CNV.
This PDF is available to Subscribers Only